The natural history of hepatitis C virus infection

Saudi Medical Journal

Volumn 24, Issue SUPPL. 2, 2003, Pages

  Al Quaiz, Mohammed N ^a   Madani, Tariq A ^c   Karawi, Mohamed A ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Armed Forces Hospital ^*  (Saudi Arabia)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; VIRUS RNA;

ACUTE HEPATITIS; AGE; ALCOHOL CONSUMPTION; ANTIVIRAL ACTIVITY; CRYOGLOBULINEMIA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; GENDER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; REVIEW; RISK FACTOR;

ACUTE DISEASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; PROGNOSIS; RISK ASSESSMENT; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 0141592505     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Feinman SV, Berris B, Bojraski S. Posttransfusion hepatitis in Toronto, Canada. Gastroenterology 1988; 95: 464-469.
2. Dienstag J. Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology 1983; 85: 439-462.
3. Kuo G, Choo QL, Alter MJ, Gitnick GL, Redeker AG, Purcelss RH, Miyamura T et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B viral hepatitis genome. Science 1989; 244: 362-364.
4. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL et al. Detection of antibodies to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500.
5. Choo QL, Weiner AJ, Overby LR, Kuo G, Houghton M, Bradley DW. Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis. Br Med Bull 1990; 46: 423-441.
6. Bortolotti F, Tagger A, Cadrobbi P, Crivellaro C, Pregliasco F, Ribero ML et al. Antibodies to hepatitis C virus in community acquired acute non-A, non-B hepatitis. J Hepatol 1991; 12: 176-180.
7. Fagan EA, Harrison TJ. Exclusion in liver by polymerase chain reaction of hepatitis B and C viruses in acute liver failure attributed to sporadic non-A, non-B hepatitis. J Hepatol 1994; 21: 587-591.
8. Hino K, Sainokami S, Shimoda K, Niwa H, Iino S. Clinical course of acute hepatitis C and changes in HCV markers. Dig Dis Sci 1994; 39: 19-27.
9. Seeff L. Natural History of Hepatitis C. Hepatology 2002; 36 Suppl 1: S35-S36.
10. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36 Suppl 1: S21-S29.
11. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98-104.
12. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.
13. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis. C. Nat Med 2000; 6: 578-582.
14. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML et al. Risk factors of evolution to cirrhosis of chronic non-A, non-B post-transfusional hepatitis. Preliminary results of recombinant alpha-2a interferon therapy. In: Shikata T, Purcell RH, Uchid R. Viral Hepatitis C, D and E. Amsterdam (NL): Elsevier Science Publishers; 1991. p. 197-200.
15. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 2592-2893.
16. Centers for Disease Control and Prevention. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. MMWR 1998; 47 (No. RR-19): 1-39.
17. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351-355.
18. Kenny-Walsh E. For the Irish Hepatology Research Group. Clinical outcome after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-1233.
19. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. For the East German Hepatitis C Study Group. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20 year multicenter study. Hepatology 2000; 32: 91-96.
20. Muller R. The natural history of hepatitis C: clinical experiences. J Hepatol 1996; 24: 52S-54S.
21. Conry-Cantilena C, Van Raden M, Gibble J, Melpolder J, Viladomiu L, Cheung L et al. Routes of infection, viremia and liver disease in asymptomatic individuals with hepatitis C virus infection. N Engl J Med 1996; 334: 1691-1696.
22. Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM et al. Outcome of outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetic studies. Hepatology 2002; 36: 993-1000.
23. Poynard T, Bedossa P, Opolon P. For the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
24. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602-610.
25. Alter MJ, Kniszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
26. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a prospective on long-term outcome. Semin liver Dis 2000; 20: 17-35.
27. Tong MJ, El-Farra NS, Reijes AR, Co RL. Clinical outcome after transfusion associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
28. Marcellin P. Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatol 2002; 36 Suppl 1: S47-S56.
29. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M et al. Influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long term retrospective cohort study. Hepatol 2001; 34: 1193-1199.
30. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D et al. Progression of fibrosis in early stages of chronic hepatitis C. Gastroenterol 2003; 124: 97-104.
31. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97: 700-706.
32. Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ et al. Influence of ethnicity in the outcome of hepatitis virus infection and cellular immune response. Hepatol 2003; 37: 590-599.
33. Yeo AET, Ghany M, Conry-Cantilena C, Melpolder JC, Kluiner DE, Shih JW et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hep 2001; 8: 256-263.
34. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695.
35. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760-764.
36. Mayo MJ, Kaplan NM, Palmer BF. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003; 325: 135-148.
37. Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M et al. Serum levels of gamma-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection. Hepatology Research 2003; 25: 14-21.
38. Angello V, Chung RT, Ksplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495.
39. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulin and cirrhosis: a meta analysis. Hepatology 2002; 36 (4 Pt 1): 978-985.
40. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-470.
41. DeCastro M, Sanchez J, Herrera JF, Chaves A, Duran R, Garcia-Buey L et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17: 551-557.